Capsaicin (Oral).

Capsicum fruit is where oral capsaicin comes from, so a capsicum extract and a capsaicin input contribute to the same capsaicinoid total. Standardisation percentage decides how much of each is actually the active.

Dihydrocapsaicin makes up a large share of natural capsaicinoids and binds the same TRPV1 vanilloid site with similar potency. Labels that quote total capsaicinoids are counting the two together.

Capsimax is a coated capsaicinoid preparation designed to release past the stomach, so it carries the identical actives with a different release profile. Stacking it with plain oral capsaicin raises the capsaicinoid total rather than adding a second mechanism.

Capsaicin drives sympathetic activity through TRPV1 sensory afferents while caffeine blocks adenosine receptors and slows breakdown of cyclic AMP. Energy expenditure and lipolysis signals arrive by two different doors, which is why thermogenic blends carry both.

EGCG slows catechol-O-methyltransferase, the enzyme that inactivates noradrenaline, while capsaicin promotes its release from sympathetic terminals. The released signal therefore persists longer at the tissue.

Gingerols and shogaols carry the same vanillyl chemistry as capsaicin and act on TRPV1, so the two produce overlapping warmth and gastric sensory signalling. Their effect on that receptor is additive rather than independent.

6-paradol and 6-gingerol from grains of paradise engage the same pungent receptor family as capsaicin and raise brown fat sympathetic drive. Their signals at that receptor family add together, so a blend should be dosed with the total in mind.

Piperine is itself a TRPV1 and TRPA1 agonist and it also slows CYP3A4 and glucuronidation, the routes that clear capsaicinoids. Both the receptor signal and the exposure to a given capsaicin dose run higher.

Casein micelles bind capsaicinoids through their hydrophobic regions, which is the reason dairy quiets pungency faster than water. Taking oral capsaicin with a casein load leaves less unbound capsaicin at the sensory receptor.

Capsaicin is a lipophilic vanillylamide with very low water solubility, so it dissolves readily in medium chain triglycerides and poorly in aqueous vehicles. Dispersing capsaicinoids in an oil phase is formulation chemistry rather than a clinical finding. The effect is on how much of the dose sits in solution, not on any extra biological action.

Phospholipid emulsifiers keep capsaicinoids dispersed in a mixed micellar phase instead of separating out of a fill. Lecithin appears in oral capsaicinoid products for that reason. This is a delivery relationship and says nothing about the size of any physiological effect.

Curcumin and capsaicin have been co-loaded into one nanoemulsion and fed together in poultry, where the authors reported changes in oxidative stress markers and intestinal morphology. Both are lipophilic actives that suit the same emulsion vehicle. The work is in birds and the endpoints are markers, so it does not establish a human effect.

Capsaicin activates TRPV1, the sensory channel that signals heat, while menthol from peppermint activates TRPM8, the channel that signals cool. The two sensations are reported together rather than one cancelling the other. Formulators pair them for the sensory result; read it as pharmacology of sensation, not as a change in absorption.

TRPV1 activation has been linked in preclinical work to endothelial nitric oxide signalling, and citrulline raises arginine availability for the same nitric oxide pathway. The overlap is mechanistic and mostly non-human. No combination trial in people supports an additive effect, so the pairing is a hypothesis rather than a measured result.

Dietary nitrate raises circulating nitrite and nitric oxide, and capsaicinoids have been described as acting on the same endothelial signalling in preclinical models. Stacking two vasodilatory inputs is worth flagging for anyone already tracking their blood pressure numbers. The additive direction is plausible on mechanism and has not been measured together.

A mouse study reported that capsaicin altered gut microbial output, with a microbiota-derived metabolite named as the intermediate. Inulin is a fermentable substrate that shifts the same microbial community. The interaction is a reasonable read of two inputs acting on one ecosystem, measured only in mice.

Capsaicin has been shown in mice to change the composition of gut bacteria and the metabolites they produce. Live cultures act on the same community from the other side. What the combination does in people has not been measured; this is a mechanistic overlap only.

A protein and fat containing meal slows gastric emptying and buffers the pungency of an oral capsaicinoid dose, which is why capsaicin products are commonly taken with food. Casein does the same and is already recorded here. The consequence is tolerability and timing, not a larger thermogenic response.

Carnitine shuttles long chain fatty acids into the mitochondrion, and capsaicinoids are studied for catecholamine driven lipolysis that supplies those fatty acids. The steps sit in sequence on paper. No trial has tested the pair, so the additive framing is mechanistic.

Bicarbonate raises gastric pH, and the burning sensation from an oral capsaicinoid dose is reported by users at the stomach as well as the mouth. Raising pH does not neutralise capsaicin, which is not acidic, so any comfort effect is on the mucosal environment rather than on the molecule. Read it as a tolerability pairing, not a potency one.